Challenges and opportunities in developing respiratory syncytial virus therapeutics

Eric A.F. Simões, John Devincenzo, Michael Boeckh, Louis Bont, James E. Crowe, Paul Griffiths, Frederick G. Hayden, Richard L. Hodinka, Rosalind L. Smyth, Keith Spencer, Steffen Thirstrup, Edward E. Walsh, Richard J. Whitley

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Two meetings, one sponsored by the Wellcome Trust in 2012 and the other by the Global Virology Foundation in 2013, assembled academic, public health and pharmaceutical industry experts to assess the challenges and opportunities for developing antivirals for the treatment of respiratory syncytial virus (RSV) infections. The practicalities of clinical trials and establishing reliable outcome measures in different target groups were discussed in the context of the regulatory pathways that could accelerate the translation of promising compounds into licensed agents. RSV drug development is hampered by the perceptions of a relatively small and fragmented market that may discourage major pharmaceutical company investment. Conversely, the public health need is far too large for RSV to be designated an orphan or neglected disease. Recent advances in understanding RSV epidemiology, improved point-of-care diagnostics, and identification of candidate antiviral drugs argue that the major obstacles to drug development can and will be overcome. Further progress will depend on studies of disease pathogenesis and knowledge provided from controlled clinical trials of these new therapeutic agents. The use of combinations of inhibitors that have different mechanisms of action may be necessary to increase antiviral potency and reduce the risk of resistance emergence.

Original languageEnglish (US)
Pages (from-to)S1-S20
JournalJournal of Infectious Diseases
Volume211
DOIs
StatePublished - Mar 15 2015

Fingerprint

Respiratory Syncytial Viruses
Antiviral Agents
Public Health
Point-of-Care Systems
Pharmaceutical Preparations
Neglected Diseases
Respiratory Syncytial Virus Infections
Virology
Controlled Clinical Trials
Drug Industry
Rare Diseases
Epidemiology
Therapeutics
Outcome Assessment (Health Care)
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Simões, E. A. F., Devincenzo, J., Boeckh, M., Bont, L., Crowe, J. E., Griffiths, P., ... Whitley, R. J. (2015). Challenges and opportunities in developing respiratory syncytial virus therapeutics. Journal of Infectious Diseases, 211, S1-S20. https://doi.org/10.1093/infdis/jiu828

Challenges and opportunities in developing respiratory syncytial virus therapeutics. / Simões, Eric A.F.; Devincenzo, John; Boeckh, Michael; Bont, Louis; Crowe, James E.; Griffiths, Paul; Hayden, Frederick G.; Hodinka, Richard L.; Smyth, Rosalind L.; Spencer, Keith; Thirstrup, Steffen; Walsh, Edward E.; Whitley, Richard J.

In: Journal of Infectious Diseases, Vol. 211, 15.03.2015, p. S1-S20.

Research output: Contribution to journalArticle

Simões, EAF, Devincenzo, J, Boeckh, M, Bont, L, Crowe, JE, Griffiths, P, Hayden, FG, Hodinka, RL, Smyth, RL, Spencer, K, Thirstrup, S, Walsh, EE & Whitley, RJ 2015, 'Challenges and opportunities in developing respiratory syncytial virus therapeutics', Journal of Infectious Diseases, vol. 211, pp. S1-S20. https://doi.org/10.1093/infdis/jiu828
Simões, Eric A.F. ; Devincenzo, John ; Boeckh, Michael ; Bont, Louis ; Crowe, James E. ; Griffiths, Paul ; Hayden, Frederick G. ; Hodinka, Richard L. ; Smyth, Rosalind L. ; Spencer, Keith ; Thirstrup, Steffen ; Walsh, Edward E. ; Whitley, Richard J. / Challenges and opportunities in developing respiratory syncytial virus therapeutics. In: Journal of Infectious Diseases. 2015 ; Vol. 211. pp. S1-S20.
@article{619e841d3c404b9082e23c4c6e9a6c50,
title = "Challenges and opportunities in developing respiratory syncytial virus therapeutics",
abstract = "Two meetings, one sponsored by the Wellcome Trust in 2012 and the other by the Global Virology Foundation in 2013, assembled academic, public health and pharmaceutical industry experts to assess the challenges and opportunities for developing antivirals for the treatment of respiratory syncytial virus (RSV) infections. The practicalities of clinical trials and establishing reliable outcome measures in different target groups were discussed in the context of the regulatory pathways that could accelerate the translation of promising compounds into licensed agents. RSV drug development is hampered by the perceptions of a relatively small and fragmented market that may discourage major pharmaceutical company investment. Conversely, the public health need is far too large for RSV to be designated an orphan or neglected disease. Recent advances in understanding RSV epidemiology, improved point-of-care diagnostics, and identification of candidate antiviral drugs argue that the major obstacles to drug development can and will be overcome. Further progress will depend on studies of disease pathogenesis and knowledge provided from controlled clinical trials of these new therapeutic agents. The use of combinations of inhibitors that have different mechanisms of action may be necessary to increase antiviral potency and reduce the risk of resistance emergence.",
author = "Sim{\~o}es, {Eric A.F.} and John Devincenzo and Michael Boeckh and Louis Bont and Crowe, {James E.} and Paul Griffiths and Hayden, {Frederick G.} and Hodinka, {Richard L.} and Smyth, {Rosalind L.} and Keith Spencer and Steffen Thirstrup and Walsh, {Edward E.} and Whitley, {Richard J.}",
year = "2015",
month = "3",
day = "15",
doi = "10.1093/infdis/jiu828",
language = "English (US)",
volume = "211",
pages = "S1--S20",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Challenges and opportunities in developing respiratory syncytial virus therapeutics

AU - Simões, Eric A.F.

AU - Devincenzo, John

AU - Boeckh, Michael

AU - Bont, Louis

AU - Crowe, James E.

AU - Griffiths, Paul

AU - Hayden, Frederick G.

AU - Hodinka, Richard L.

AU - Smyth, Rosalind L.

AU - Spencer, Keith

AU - Thirstrup, Steffen

AU - Walsh, Edward E.

AU - Whitley, Richard J.

PY - 2015/3/15

Y1 - 2015/3/15

N2 - Two meetings, one sponsored by the Wellcome Trust in 2012 and the other by the Global Virology Foundation in 2013, assembled academic, public health and pharmaceutical industry experts to assess the challenges and opportunities for developing antivirals for the treatment of respiratory syncytial virus (RSV) infections. The practicalities of clinical trials and establishing reliable outcome measures in different target groups were discussed in the context of the regulatory pathways that could accelerate the translation of promising compounds into licensed agents. RSV drug development is hampered by the perceptions of a relatively small and fragmented market that may discourage major pharmaceutical company investment. Conversely, the public health need is far too large for RSV to be designated an orphan or neglected disease. Recent advances in understanding RSV epidemiology, improved point-of-care diagnostics, and identification of candidate antiviral drugs argue that the major obstacles to drug development can and will be overcome. Further progress will depend on studies of disease pathogenesis and knowledge provided from controlled clinical trials of these new therapeutic agents. The use of combinations of inhibitors that have different mechanisms of action may be necessary to increase antiviral potency and reduce the risk of resistance emergence.

AB - Two meetings, one sponsored by the Wellcome Trust in 2012 and the other by the Global Virology Foundation in 2013, assembled academic, public health and pharmaceutical industry experts to assess the challenges and opportunities for developing antivirals for the treatment of respiratory syncytial virus (RSV) infections. The practicalities of clinical trials and establishing reliable outcome measures in different target groups were discussed in the context of the regulatory pathways that could accelerate the translation of promising compounds into licensed agents. RSV drug development is hampered by the perceptions of a relatively small and fragmented market that may discourage major pharmaceutical company investment. Conversely, the public health need is far too large for RSV to be designated an orphan or neglected disease. Recent advances in understanding RSV epidemiology, improved point-of-care diagnostics, and identification of candidate antiviral drugs argue that the major obstacles to drug development can and will be overcome. Further progress will depend on studies of disease pathogenesis and knowledge provided from controlled clinical trials of these new therapeutic agents. The use of combinations of inhibitors that have different mechanisms of action may be necessary to increase antiviral potency and reduce the risk of resistance emergence.

UR - http://www.scopus.com/inward/record.url?scp=84925219445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925219445&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiu828

DO - 10.1093/infdis/jiu828

M3 - Article

VL - 211

SP - S1-S20

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

ER -